Acute kidney injury (AKI) is a common, severe emergency case in clinics, with high incidence, significant mortality and increased costs. Despite development in the understanding of its pathophysiology, the therapeutic choices are still confined to dialysis and renal transplantation. Considering their antiapoptotic, immunomodulatory, antioxidative and pro-angiogenic effects, mesenchymal stem cells (MSCs) may be a promising candidate for AKI management. Based on these findings, some clinical trials have been performed, but the results are contradictory (NCT00733876, NCT01602328). The low engraftment, poor survival rate, impaired paracrine ability and delayed administration of MSCs are the four main reasons for the limited clinical efficacy. Investigators have developed a series of preconditioning strategies to improve MSC survival rates and paracrine ability. In this review, by summarizing these encouraging studies, we intend to provide a comprehensive understanding of various preconditioning strategies on AKI therapy and improve the prognosis of AKI patients by regenerative medicine.
tubular epithelial cell repair. 5 Among a variety of stem cells, mesenchymal stem cells (MSCs) have emerged as the most promising candidates for AKI therapy given their low immunogenicity, high multipotential differentiation ability, invasiveness of isolation and abundant distribution. [6] [7] [8] Despite the encouraging results of MSCs usage in animal models, a huge gap exists between scientific observation and clinical application. In 2017, Swaminathan et al provided a phase 2, randomized, double-blind, multicenter trial on the use of MSCs in patients with post-cardiac surgical AKI (NCT01602328). 9 After randomizing 156 adult subjects, they found that time to renal function recovery, need for dialysis, and 30-day all-cause mortality were all compatible between the two groups.
What makes MSCs lose their magic power clinically? There is growing evidence that the regenerative effect of MSCs might be mediated predominantly by paracrine action, rather than direct differentiation into target cells. [10] [11] [12] [13] Once injected into an injured tissue, MSCs face a harsh environment, including reactive oxygen species (ROS) and anoikis, which are largely generated after AKI that may promote MSC apoptosis. [14] [15] [16] It is reported that more than 80%-90% of grafted cells will die within the first week after injection, 17 and the remaining 9%-19% cells may be trapped in liver, lungs and spleen. 18 Impaired MSC potency/biological activity in vivo was also reported. Silva et al concluded in their article that the limited clinical efficacy of MSCs might result from the low amount of engraftment, poor survival rate, impaired paracrine ability and delayed administration 19 ( Figure 1 ).
To overcome this obstacle, some approaches to improve the ability of grafted MSCs have been explored in recent years. Investigators try to increase the number of injected cells, but it may be risky due to disturbance in blood flow causing embolism problems. 20 Others attempt to inject cells directly into the damaged tissue, but the invasive procedures include a high risk of haemorrhage, and the number of injected MSCs is also inaccurate, as most of the cells may escape from the injected site. 21, 22 Preconditioning is a promising strategy for optimizing MSCs before their transplantation. Based on the way MSCs operate, these strategies are designed to increase the survival rate of MSCs in injured tissues, enhance their paracrine ability or help them migrate to the target tissue ( Figure 2 ). Previously, we have discussed those preconditioning strategies for enhancing the migratory ability of MSCs in AKI. 23 In this review, we focus on summarizing the different preconditioning strategies for increasing the MSCs survival rate or paracrine ability in AKI models. Only articles that demonstrated a clear mechanism are included in our review. We look forward a bright future in which the preconditioning strategy can be used to increase the function of MSCs and, consequently, to achieve long-term benefits of MSCs therapies in AKI patients.
| STRATEGIES TO IMPROVE MSCS

SURVIVAL RATES
The low survival rate of transplanted MSCs remains an important limitation for MSC therapy. 17, 24 Anoikis, ischemia, inflammation and imbalance between ROS and antioxidant are likely the major causes of cell death following transplantation. [25] [26] [27] 
| Genetic modification
As discussed above, the imbalance between ROS and antioxidants in the AKI microenvironment was regarded as the main reason for poor cell survival rate. Genetic modification to make MSCs overexpress cytokine genes or antiapoptotic genes significantly improved their survival rate in injured tissues. 46, 47 Heme oxygenase-1 (HO-1), a stress-inducible enzyme that can catalyze the pro-oxidant heme into biliverdin, CO and free-iron, exerted powerful antioxidant effects. pro-angiogenic activities. 65, 66 Similar to the preconditioning strategies mentioned above, some methods have also been explored to enhance MSC paracrine ability after transplantation (Table 2) .
| Hypoxia
Different from the atmospheric oxygen tension (21%) in a standard cell culture environment, a hypoxic environment is experienced by transplanted MSCs under ischemic conditions. Culturing in oxygen tension that more closely resembles the situation in vivo has been confirmed to help considerably with many aspects, including cell 27 Liu et al used muscone to precondition MSCs, and higher levels of bone morphogenetic protein-7 (BMP-7) were observed both by real-time qPCR and ELISA. 32 Interestingly, Xinaris et al pretreated MSCs with IGF-1. After full washout, they still observed a 10-fold increase of IGF-1 in the preconditioning group. 35 MSCs could possibly amplify their regenerative effects through autocrine activity.
Prostaglandin E2 (PGE2) was thought to be important for MSCmediated immune modulation. 
| Improvement of culture condition
Improved culture conditions were also beneficial for MSCs' paracrine ability. 3D spheroid culture increased the secretion of VEGF, bFGF, epidermal growth factor (EGF), HGF, IGF and tumour necrosis factor-alpha stimulated gene/protein 6 (TSG-6). 39 In 2013, Katsuno et al cultured MSCs in a low serum culture medium containing (2% fetal bovine serum) (lMSCs). They observed that lMSCs secreted higher levels of HGF and VEGF compared to the MSCs cultured in high serum (hMSCs). After transplantation into rat models of folic acid-induced AKI, lMSCs significantly attenuated acute renal damage and showed less interstitial fibrosis change on day 14. 
| Genetic modification
Compared with other preconditioning strategies, genetic modification is a more accurate way to enhance MSC paracrine ability. Overexpression of chemokine (C-X-C motif) receptor 4 (CXCR4) in BMSCs, using lentivirus vector, resulted in higher levels of BMP-7, HGF and IL-10. Significantly improved renal function, reduced ATN scoring, more PCNA tubular cells and fewer TUNEL tubular cells were also observed using in vivo studies. 76 Lipocalin 2 (Lcn2) was thought to be a cytoprotective factor against AKI due to its important role in regeneration and proliferation of tubular epithelial cells. 77 showed that these effects could be partially abolished by IKK XII (NF-κB inhibitor), indicating the role of NF-κB in regulating cell viability and migration. 89 These studies confirmed that the activation of NF-κB might be involved in the cytoprotective, migratory and paracrine processes of MSCs. In contrast, decreased NF-κB activity was observed in Rap1-/-BMSCs, which displayed more resistance to apoptosis and presented better cardioprotective effects in myocardial infarction mice than wild-type BMSCs. 90 Similarly, the results from mice fed a high fat diet (HFD) identified HFD-induced activation of NF-κB in MSCs, contributing to the reduced expression of VEGFA and bFGF. 91 In conclusion, the exact role NF-κB plays in other routes of delivery in AKI models. 96 After multivariable meta-regression analysis, they concluded no difference in SCr reduction was found between different delivery routes. These confusing results may come from the different types of cells used in these studies.
| NEED FOR A STANDARD MSCS REGIMEN FOR AKI TH ERAPY
Intravenously delivered MSCs might be retained in the lung capillaries, which reduced their therapeutic effects, while the smaller size of EVs made them easily pass through lung capillaries and migrate towards injured tissue, presenting similar therapeutic effects as intraarterial injection. 92, 97 Due to the limitations of these meta-analyses, it is still difficult to say which delivery route is the best for AKI management. We need more studies to answer this question.
Last but not the least, the issue of humoural or cellular responses should still be considered for the clinical application of MSCs. Until now, only one study compared the safety and efficacy of allogeneic with autologous MSCs in AKI models. Different doses of allogeneic and autologous MSCs were infused in rats with I/R-induced AKI.
Allogeneic and autologous MSCs both presented immediate renoprotective effects. After a 3-month follow-up period, renal function was preserved and no significant MSC-induced side effects occurred in both groups. In addition to the safety and efficacy of allogeneic MSCs, a panel of fibrosis-related genes were decreased in the allogeneic group, demonstrating the potential better therapeutic effects of allogeneic MSCs. 98 Similar results were obtained from POSEI-DON-DCM trial, which demonstrated the safety and supported the greater benefit of allogeneic than autologous MSCs for nonischemic dilated cardiomyopathy patients. 99 Allogeneic MSCs can be advantageous to autologous ones for a number of reasons, such as low expenses, high quality and easy processes during the harvesting period. 100 The main concern of allogeneic MSC application arises from their potential antigenicity. Due to the absence of major histocom- 
| CONCLUSION AND FUTURE
PERSPE CTIVE
In conclusion, how much of a role MSCs exert clinically in AKI largely depends on their survival, paracrine and migration ability. Without a doubt, various preconditioning strategies improve MSCs survival and paracrine ability, exaggerating their beneficial effects.
Due to the huge heterogeneity in MSCs therapeutic regimens, it is difficult to demonstrate which preconditioning strategy is the best one. Different donors, sources, route timing and doses of transplanted MSCs may need different preconditioning strategies. The advantages and disadvantages of different preconditioning strategies mentioned in this article are listed in Table 3 . 19, [103] [104] [105] [106] [107] [108] A better understanding of the molecular and cellular mechanisms underlying the preconditioning strategy may help considerably to expand its application in AKI and avoid potential side effect. A preconditioning strategy that can not only enhance the survival, paracrine and migration ability of MSCs but also have no potential adverse effect is the most suitable preconditioning strategy for AKI therapy. We look forward to an optimistic future of MSCs therapy in AKI and call for more research in this area. 
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